MDM2 and prostate carcinoma: Others have previously shown that PAK6 phosphorylates MDM2 at the Ser186 and Thr158 sites, activating MDM2 to ubiquitinate the androgen receptor and inhibit tumor growth in prostate cancer cells [30].